CTRI/2021/11/037885尚未招募未知
An open label non-randomized preliminary study comparing two targeted phototherapy devices i.e. daily use of home-based hand-held Narrow Band UVB comb device versus biweekly hospital-based excimer light therapy in treatment of localized vitiligo
AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Consecutive patients of localized vitiligo i.e. <=2% BSA or <=10 patches.
- •2. Patients >=18 years of age.
- •3. Patients who have not taken any topical therapy in last 2 weeks or systemic therapy in last 4 weeks
- •4. Patients giving consent for using hand held NB-UVB/excimer light
排除标准
- •1. Patients with rapidly spreading vitiligo i.e.development of >= 5 new lesions in the past 1 month or >= 15 lesions in the past 3 months.
- •2. Patients with recalcitrant forms of vitiligo i.e., lip-tip vitiligo, segmental vitiligo, genital vitiligo and with predominant leukotrichia on patches.
- •3. Patients with concomitant photo-aggravated dermatoses.
- •4. Patients who are unable to adhere to instructions on use of the hand-held NB-UVB comb device or maintain it or patients unable to visit the hospital for excimer light therapy
研究者
相似试验
招募中
不适用
To compare hand held ultraviolet device verses whole body ultraviolet device in treatment of vitiligo patientCTRI/2019/08/020818AIIMS DELHI
未知
1 期
A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric CancerGastric CancerJPRN-jRCT2080220881AstraZeneca
已完成
不适用
A safety and efficacy trial of the SureflO2™ oxygen mask which incorporates a visual gas flow indicator into a standard oxygen mask.Oxygen Delivery ErrorsAirway ManagementRespiratory - Other respiratory disorders / diseasesAnaesthesiology - Other anaesthesiologyACTRN12619000323123VPAS Group Pty Ltd249
已完成
1 期
A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy VolunteersStem cell mobilisationBlood - Haematological diseasesACTRN12614000200684Antisense Therapeutics10
进行中（未招募）
1 期
Study that tested S64315 plus different standard treatments in patients with breast cancerEUCTR2019-000998-23-ESInstitut de Recherches Internationales Servier